Toad Talks: Conservation and Ecology of the Sonoran Desert Toad in the USA Monsoon 2025
Toad Talk Series presented by the Church of the Sacred Synthesis. 5 Episodes during the Monsoon of 2025 in Southeastern, AZ around Tucson.
Category: DEA
In this conversation, Mitch Schultz and Ian Benouis explore the transformative power of plant medicines, particularly in the context of healing trauma experienced by veterans. They discuss their personal journeys with psychedelics, the importance of community and support in the healing process, and the potential for these medicines to help individuals reconnect with their true selves. The conversation emphasizes the need for a holistic approach to healing that integrates both traditional and modern practices, and the role of veterans in leading this change in society.
In a discussion about Psilomethoxin, Gabe, Ben, Ian and Ryan explore its unique properties, effects compared to traditional psychedelics, and potential benefits for veterans. They emphasize community drug development for accessible healing, the evolving psychedelic industry, and the impact of patents on substance availability. Psilomethoxin serves as both an on-ramp and off-ramp for psychedelic experiences.
keywords veteran trauma, psychedelics, healing, mental health, psilomethoxin, gut health, PTSD, natural medicine, community support, citizen science hashtags#psilomethoxin#sacredsynthesis#toadshrooms#bufoboomers#churchofpsilomethoxin#toadally#hikrodosing#psilotoad#toadstool#🐸🍄 summary In this episode, the hosts discuss the profound impact of veteran trauma and the potential healing properties of psychedelics, particularly psilomethoxin. They explore personal stories of trauma, the importance of gut health, and the mental health […]
In the inaugural episode of the Tryptamine Cowboy Chronicles, hosts Ian Benouis, Gabe Hardy, and Ben Moore discuss the Church of the Sacred Synthesis’ mission focused on the healing properties of psychedelics, particularly Psilomethoxin. They highlight the importance of community in accessing these substances and address legal challenges around psychedelic therapies. The hosts share personal experiences, emphasizing the potential of Psilomethoxin for treating PTSD, especially among veterans. They aim to create a pre-order model to bring Psilomethoxin to market as an over-the-counter supplement. Emphasizing transparency and community involvement, the episode encourages listeners to learn and participate in this healing journey.
“these data suggest that R-MDMA could be a more viable therapeutic option for the treatment of PTSD and other disorders for which S/R-MDMA is currently being investigated” since “R-MDMA unlike racemic MDMA, did not increase locomotor activity, produce signs of neurotoxicity, or increase body temperature.
A key pharmacological difference between R-MDMA and racemic MDMA is that R-MDMA has much lower potency as a dopamine releaser. Together, these results indicate that the prosocial and therapeutic effects of S/R-MDMA may be SEPARABLE from the stimulant, thermogenic, and potential neurotoxic effects.”
Ian Benouis 